Neuromuscular Ultrasound in ALS

checkorphan
Learn more about:
Amyotrophic lateral sclerosis
Related Clinical Trial
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS Remote Pulmonary Function Testing and Nurse Coaching in ALS Coping Effectiveness Training for ALS Exposure to Neurotoxins as Risk Factors for ALS Assessment of Voluntary and Reflex Cough in Patients With ALS Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis Trial of Oxaloacetate in ALS Safety Study of Oral Edaravone Administered in Subjects With ALS Neuromuscular Ultrasound in ALS A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

Brief Title

Neuromuscular Ultrasound in ALS

Official Title

Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study

Brief Summary

      Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease
      affecting motor neurons. Early diagnosis is essential for the success of clinical trials and
      objective biomarkers are needed for monitoring disease progression. Nerve and muscle
      ultrasound may provide this information.

      This study will collect pilot data to evaluate the value of muscle and nerve ultrasound to
      identify and monitor disease progression in ALS.

Study Type

Observational

Primary Outcome

Abnormalities at onset: Ultrasound vs. Electromyography

Secondary Outcome

 Ultrasound Predicting Outcome at 1 year

Condition

ALS

Intervention

Ultrasound of nerve and muscle

Study Arms / Comparison Groups

 Control Group
Description:  No intervention to be performed.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Other

Estimated Enrollment

40

Start Date

February 2013

Completion Date

March 2015

Primary Completion Date

March 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects referred to the electromyography laboratory for ALS.

        Exclusion Criteria:

          -  Patients with known comorbid myopathy or neuropathy will be excluded from the study.

          -  Patients unable to provide their own consent will be excluded.

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT01785550

Organization ID

Pro00042025

Responsible Party

Sponsor

Study Sponsor

Duke University

Study Sponsor

, ,

Verification Date

March 2015